Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 5/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27649898 | 0.77 | NPC1 (0.39) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL1716511 | 0.75 | PSEN1 (0.53) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL25186762 | 0.73 | RAB9A (0.48) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL30419303 | 0.73 | RAB9A (0.48) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL1715849 | 0.71 | LCK (0.41) | LCK | |
| SCHEMBL6643291 | 0.71 | NPC1 (0.67) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL1715852 | 0.70 | CA1 (0.43) | LCK | |
| SCHEMBL8283217 | 0.69 | LCK (0.43) | ALDH1A1GAALCK | |
| SCHEMBL5524301 | 0.69 | MAPT (0.41) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL3615179 | 0.69 | MAPT (0.41) | MAPTKDM4ESMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709018-B1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| EP-1709018-B1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-7759377-B2 | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-7759377-B2 | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-7759377-B2 | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-20060293366-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2006-12-28 | — | — | US | disclosed |
| EP-1709018-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | Sanofi-Aventis (FR) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073202-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073202-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | MAPT 12/4885KDM4E 1544/4885SMN1; SMN2 1028/4885 |
| US-20060293366-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | MAPT 12/4885KDM4E 1544/4885SMN1; SMN2 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.